Table 1.
Patient characteristics.
| Characteristic | Discovery cohort (2011–2017) | Validation cohort (2017–2020) | Total |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Overall | 59 (100) | 46 (100) | 105 (100) |
| Age | |||
| Median (range) | 62 (16–88) | 66 (31–88) | 63 (16–88) |
| Sex | |||
| Male | 33 (56) | 27 (59) | 60 (57) |
| Female | 26 (44) | 19 (41) | 45 (43) |
| Stage | |||
| II | 0 (0) | 2 (4) | 2 (2) |
| III | 1 (2) | 5 (11) | 6 (6) |
| IV | 58 (98) | 39 (85) | 97 (92) |
| Mutation status | |||
| BRAF | 18 (31) | 14 (30) | 32 (31) |
| NRAS | 8 (14) | 10 (22) | 18 (17) |
| None | 32 (54) | 20 (43) | 52 (50) |
| Prior immune checkpoint blockade | |||
| Yes | 16 (27) | 6 (13) | 22 (21) |
| No | 43 (73) | 40 (87) | 83 (79) |
| Treatment | |||
| Pembrolizumab | 23 (39) | 9 (20) | 32 (31) |
| Nivolumab | 11 (19) | 14 (30) | 25 (24) |
| Ipilimumab plus nivolumab | 25 (42) | 23 (50) | 48 (46) |
| Best overall response | |||
| Complete response | 10 (17) | 11 (24) | 21 (20) |
| Partial response | 16 (27) | 8 (17) | 24 (23) |
| Stable disease | 17 (29) | 8 (17) | 25 (24) |
| Progressive disease | 16 (27) | 18 (39) | 34 (32) |
| Long-term benefit | |||
| Yes | 13 (22) | 9 (20) | 22 (21) |
| No | 37 (63) | 27 (59) | 64 (61) |
CR complete response, PR partial response, SD stable disease, PD progressive disease.